Siemens and Healthineers: Valuing the IPO Custom Case Solution & Analysis

Evidence Brief: Siemens and Healthineers IPO

1. Financial Metrics

• Revenue: 13.8 billion EUR in fiscal year 2017.
• Profitability: Adjusted EBIT of 2.5 billion EUR; profit margin of 18.1 percent.
• Segment Performance: Imaging segment contributed 8.2 billion EUR (59 percent of revenue). Diagnostics contributed 3.9 billion EUR (28 percent). Advanced Therapies contributed 1.5 billion EUR (11 percent).
• Growth: Revenue growth of 3.8 percent on a comparable basis from 2016 to 2017.
• Capital Structure: Planned IPO of a 15 percent minority stake. Siemens AG to retain 85 percent ownership.
• Market Multiples: Peer group EV/EBITDA ranges from 12x to 16x. Peer group P/E ratios range from 20x to 25x.

2. Operational Facts

• Headcount: Approximately 47,000 employees globally.
• Market Position: Number one or two position in imaging (MRI, CT, X-ray) and clinical diagnostics.
• R and D Investment: Approximately 1.2 billion EUR annually to support digital health and precision medicine.
• Geography: Operations in over 70 countries; significant installed base of over 600,000 systems.

3. Stakeholder Positions

• Joe Kaeser (Siemens CEO): Views the healthcare unit as a fleet of ships rather than a single tanker; seeks to eliminate the conglomerate discount.
• Michael Sen (Siemens Healthcare Chairman): Emphasizes the need for Healthineers to have its own currency for acquisitions.
• Bernd Montag (Healthineers CEO): Focused on the transition from a hardware provider to a clinical partner and digital leader.
• Institutional Investors: Concerned about the 85 percent control retained by Siemens and potential conflicts of interest.

4. Information Gaps

• Specific cost of capital (WACC) calculations for the standalone healthcare entity versus the Siemens parent.
• Detailed breakdown of the 15.3 billion EUR in liabilities assigned to the healthcare unit.
• Projected dividend payout ratio for the new public entity.

Strategic Analysis

1. Core Strategic Question

• How should Siemens price the Healthineers IPO to maximize the valuation of its retained 85 percent stake while providing enough upside to ensure a successful public market debut?
• How can the entity decouple its valuation from the Siemens conglomerate discount?

2. Structural Analysis

The healthcare equipment industry features high barriers to entry due to massive R and D requirements and regulatory hurdles. Siemens Healthineers operates from a position of strength in Imaging but faces stagnant growth in Diagnostics. The shift toward value-based healthcare requires a transition from selling machines to providing integrated data solutions. The current conglomerate structure restricts the unit from pursuing large-scale M and A because its capital allocation is tied to the parent company industrial cycles. By carving out the unit, Siemens creates a pure-play med-tech stock that appeals to a different investor base than the industrial parent.

3. Strategic Options

Option 1: Conservative Pricing (26.00 to 28.00 EUR per share)

• Rationale: Ensures a significant first-day pop to build investor confidence and long-term demand.
• Trade-offs: Leaves money on the table for the parent company; may signal weakness in the business model.
• Resources: Minimal additional marketing; relies on existing anchor investors.

Option 2: Aggressive Valuation (30.00 to 32.00 EUR per share)

• Rationale: Maximizes immediate capital proceeds for Siemens AG and sets a high benchmark for future equity-based acquisitions.
• Trade-offs: High risk of a flat or negative post-IPO performance if market conditions shift; could alienate institutional buyers.
• Resources: Intense roadshow efforts and high-pressure book-building.

4. Preliminary Recommendation

Siemens should pursue Option 1. The primary goal of this IPO is not immediate cash extraction but the creation of a high-performing independent currency. A successful debut at a conservative price point will facilitate the eventual sell-down of more shares at higher valuations. Given the 85 percent retention, the long-term appreciation of the remaining stake is far more valuable than an extra 2 EUR per share on the initial 15 percent float.

Implementation Roadmap

1. Critical Path

• Phase 1: Final Pricing and Allocation (Days 1-5): Set the final offer price based on the lower end of the range to ensure oversubscription. Allocate shares to long-term institutional investors rather than short-term flippers.
• Phase 2: Governance Separation (Days 6-60): Establish an independent board structure that includes healthcare industry veterans not affiliated with Siemens AG. Define clear protocols for inter-company transactions to mitigate conflict of interest concerns.
• Phase 3: Digital Transformation Pivot (Days 61-90): Announce the first major standalone partnership or acquisition in the digital health space to demonstrate the utility of the new equity currency.

2. Key Constraints

• Parental Influence: The 85 percent ownership stake may lead the market to continue applying a conglomerate discount if the board appears subservient to Siemens AG.
• Market Volatility: Global trade tensions or shifts in healthcare reimbursement policies could depress multiples during the stabilization period.

3. Risk-Adjusted Implementation Strategy

To mitigate the risk of investor skepticism regarding independence, the CEO must have a separate incentive structure tied solely to Healthineers performance, not Siemens AG stock. Contingency plans include a deferred share buyback program if the stock falls 10 percent below the IPO price in the first quarter of trading. This signals management confidence in the standalone valuation.

Executive Review and BLUF

1. BLUF

The Siemens Healthineers IPO is the correct mechanism to unlock shareholder value. The entity should be priced at 28.00 EUR per share to ensure a successful market entry. While this leaves immediate capital on the table, it establishes a credible equity currency for future M and A and addresses the conglomerate discount affecting the parent company. Success depends on convincing the market that Healthineers is an independent med-tech leader rather than a Siemens subsidiary. The 18 percent EBIT margin and 600,000 system installed base provide a margin of safety that justifies a premium over diversified industrial peers.

2. Dangerous Assumption

The analysis assumes that public market investors will overlook the 85 percent control retained by Siemens AG. If the parent company uses Healthineers as a source of cash for other industrial segments through aggressive dividends, the pure-play valuation will collapse.

3. Unaddressed Risks

4. Unconsidered Alternative

A full spin-off to existing Siemens shareholders, similar to the Osram transaction, was not fully explored. This would have eliminated the control issue immediately and potentially accelerated the removal of the conglomerate discount, though it would not have raised immediate capital for the parent.

5. Verdict

APPROVED FOR LEADERSHIP REVIEW